Author name: DrugPatentWatch

Biosimilars, highly similar versions of reference biologics, have the potential to significantly impact population health management initiatives by increasing access […]

Pharmaceutical companies are increasingly recognizing the limitations of relying on expensive and often delayed third-party analysts for business intelligence. This

The advent of biosimilars has significantly altered the dynamics of the generic drug industry in Europe. Biosimilars are biological products

The pharmaceutical industry is a complex and competitive landscape, especially after the approval of an Abbreviated New Drug Application (ANDA).

The global generic drug market is expected to grow from $435.3 billion in 2023 to $655.8 billion by 2028, at

The pharmaceutical industry is undergoing a significant shift towards digital transformation, and generic drug development is no exception. This transformation

Generic drug development is a cornerstone of modern healthcare, offering affordable alternatives to brand-name medications while maintaining the same quality,

The landscape of healthcare is increasingly shaped by the accessibility and affordability of medications, with generic drugs playing a pivotal

The generic drug market is a highly competitive and dynamic industry, with both opportunities and challenges. To succeed, generic drug